Does direct-to-consumer marketing of medical technologies undermine the physician-patient relationship?

American Journal of Bioethics

Volumn 9, Issue 4, 2009, Pages 22-23

  Rosenberg, Leah ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADVERTIZING; ADVISORY COMMITTEE; ANXIETY; COMPUTER ASSISTED TOMOGRAPHY; DOCTOR PATIENT RELATION; ETHICS; EVIDENCE BASED MEDICINE; FEAR; HEALTH CARE DELIVERY; HUMAN; MASS SCREENING; MEDICAL TECHNOLOGY; METHODOLOGY; NOTE; PATIENT PARTICIPATION; PRACTICE GUIDELINE; PRIMARY HEALTH CARE; PRIMARY PREVENTION; RISK ASSESSMENT; RISK FACTOR; SOCIAL MARKETING; TREATMENT WITHDRAWAL; UNITED STATES; UTILIZATION REVIEW;

ADVERTISING AS TOPIC; ADVISORY COMMITTEES; ANXIETY; BIOMEDICAL TECHNOLOGY; EVIDENCE-BASED MEDICINE; FEAR; HEALTH SERVICES ACCESSIBILITY; HUMANS; MASS SCREENING; PATIENT PARTICIPATION; PHYSICIAN-PATIENT RELATIONS; PRACTICE GUIDELINES AS TOPIC; PRIMARY HEALTH CARE; PRIMARY PREVENTION; RISK ASSESSMENT; RISK FACTORS; SOCIAL MARKETING; TOMOGRAPHY, X-RAY COMPUTED; UNITED STATES; WITHHOLDING TREATMENT;

EID: 65249171386     PISSN: 15265161     EISSN: 15360075     Source Type: Journal    
DOI: 10.1080/15265160802716852     Document Type: Article

References (5)

1. Beauchamp, T. and Childress, J. 2001. Principles of Biomedical Ethics, 5th ed. Oxford: Oxford University Press.
2. Burger, I. M., and Kass, N. E. 2009. Screening in the dark: Ethical considerations of providing screening tests to individuals when evidence is insufficient to support screening populations. American Journal of Bioethics 9(4): 3-14.
3. Halpern, J. 2003. Responding to the need behind the question "Doctor, if this were your child what would you do?" Journal of Clinical Ethics 14(Spring-Summer/1-2): 71-78.
4. Mohrmann, M. E. 2005. Attending Children: A Doctor's Education. Washington, DC: Georgetown University Press.
5. United States Preventative Task Force. Available at http://www. ahrq.gov/clinic/uspstfix.htm (accessed February 23, 2009).